Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...

Trevi Therapeutics (TRVI) surges 40% premarket as Haduvio proves effective in reducing chronic coughing in trials.

New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy ...

Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...

Trevi Therapeutics plans to discuss the next steps with the FDA and anticipates initiating the next study after receiving the agency’s input. The positive trial results have clearly resonated with ...

Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...

The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...

Fintel reports that on March 10, 2025, Raymond James upgraded their outlook for Trevi Therapeutics (NasdaqGM:TRVI) from ...